EBM | Q: … “What is the medical evidence that Ruxolitinib is effective and safe in patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera?”
Source: Evidence Resource, Doctor Evidence; COVID-19 …; Search Query and Summary by Evidenza Precision Medicine.
“What is the medical evidence about adding Hydroxyurea in combination with Ruxolitinib will improve clinical responses in hyperproliferative forms of myelofibrosis?”
Link(s) to Relevant Study(s)
- Published: 17 April 2019; https://doi.org/10.1002/cam4.2147; Citations: 1[Correction added on 10 May 2019, after first online publication: The current address of the co‐author, Claudio Cerchione, has been added in this version as his second affiliation.]; Journal Article, Research Support, Non-U.S. Gov’t; © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.; Volume 8, Issue 6; June 2019; Pages 2802-2809
- Published: 27 September 2017; Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly; https://link.springer.com/article/10.1007%2Fs12185-017-2333-y;
- Published: 27 May 2018; https://link.springer.com/article/10.1007%2Fs00277-018-3365-y; Griesshammer, M., Saydam, G., Palandri, F. et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol 97, 1591–1600 (2018). https://doi.org/10.1007/s00277-018-3365-y
Summary (or Screen Shot) of Relevant Data Specific to Question
- Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF). However, no clear survival benefit has been demonstrated, which may in part reflect suboptimal drug exposure related to lower dosages needed to minimize hematological toxicity, specifically cytopenias. Furthermore, the optimal management of specific conditions such as leukocytosis or thrombocytosis in patients under ruxolitinib therapy is still undefined. In these cases, combining ruxolitinib with a cytoreductive agent like hydroxyurea might improve hematological response. This observational multi-center study enrolled 20 adult patients with intermediate- or high-risk primary MF, post- polycythemia vera MF, or postessential thrombocythemia MF with hyperproliferative manifestations of the disease and WBC and/or platelet counts not controlled by ruxolitinib therapy. The patients received treatment with a combination of ruxolitinib and hydroxyurea. A clinical response of any type was obtained in 8 patients (40%) during ruxolitinib monotherapy and in 17 patients (85%) during ruxolitinib-hydroxyurea combination (P = 0.003). After a median duration of 12.4 months of combination therapy, 16/20 patients had a hematological response; 14/17 patients who had started combination therapy to control WBC count and 2/3 who started in order to reduce platelets count. The number of patients requiring ruxolitinib dosage reduction or discontinuations was lower during combination therapy and, at the end of follow-up the median ruxolitinib dose was increased in 50% of patients. In conclusion, the combination of hydroxyurea with ruxolitinib yielded a high clinical response rate and increased ruxolitinib exposure in patients with hyperproliferative forms of MF. Source: © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
- Ruxolitinib, a potent JAK1/JAK2 inhibitor, was found to be superior to the best available therapy (BAT) in controlling hematocrit, reducing splenomegaly, and improving symptoms in the phase 3 RESPONSE study of patients with polycythemia vera with splenomegaly who experienced an inadequate response to or adverse effects from hydroxyurea. We report findings from a subgroup analysis of Japanese patients in RESPONSE (n = 18). The composite response rate (hematocrit control and spleen response) was higher in patients receiving ruxolitinib (50.0%) than in those receiving BAT (8.3%). A total of 50.0% of patients randomized to ruxolitinib achieved a spleen response vs 8.3% of those receiving BAT; 100 and 33.3% of patients in the respective groups achieved hematocrit control, with mean hematocrit in ruxolitinib-treated patients remaining stable at < 45% throughout the study. Similarly, a higher proportion of ruxolitinib-treated patients achieved complete hematologic remission (33.3 vs 16.7%). Ruxolitinib also led to rapid improvements in pruritus. All responses with ruxolitinib were durable to week 80, and its safety profile was consistent with that in the overall study. These findings suggest that ruxolitinib is an effective and well-tolerated treatment option for Japanese patients with polycythemia vera with an inadequate response to or adverse effects from hydroxyurea. https://link.springer.com/article/10.1007%2Fs12185-017-2333-y#citeas
- RESPONSE-2 is a phase 3 study comparing the efficacy and safety of ruxolitinib with the best available therapy (BAT) in hydroxyurea-resistant/hydroxyurea-intolerant polycythemia vera (PV) patients without palpable splenomegaly. This analysis evaluated the durability of the efficacy and safety of ruxolitinib after patients completed the visit at week 80 or discontinued the study. Endpoints included proportion of patients achieving hematocrit control (< 45%), proportion of patients achieving complete hematologic remission (CHR) at week 28, and the durability of hematocrit control and CHR. At the time of analysis, 93% (69/74) of patients randomized to ruxolitinib were receiving ruxolitinib; while in the BAT arm, 77% (58/75) of patients crossed over to ruxolitinib after week 28. No patient remained on BAT by week 80. Among patients who achieved a hematocrit response at week 28, the probability of maintaining response up to week 80 was 78% in the ruxolitinib arm. At week 80, durable CHR was achieved in 18 patients (24%) in the ruxolitinib arm versus 2 patients (3%) in the BAT arm. The safety profile of ruxolitinib was consistent with previous reports. These data support that ruxolitinib treatment should be considered also as a standard of care for hydroxyurea-resistant/hydroxyurea-intolerant PV patients without palpable splenomegaly.; https://link.springer.com/article/10.1007%2Fs00277-018-3365-y
Evidenza | Call to Action FOR DOCTORS
Not at this time.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Nothing contained on or linked to through this site should be construed as medical advice and should not be relied upon for medical diagnosis or treatment. Understand that these studies, reviews, abstracts, tables, etc., are derived from medical literature, expert analysis of the data as reported by these sources. However Evidenza, Concierge Medicine Today and its affiliated partners or representatives or employees do not recommend or endorse any particular healthcare provider, drug or medical journal source. We are not liable for any individual patient’s potential or actual outcome as a result of receiving treatment based on any of the literature, statements or physicians using through this information. You may not copy, reproduce, distribute, transmit, mirror, frame, scrape, extract, wrap, create derivative works of, reverse engineer, decompile or disassemble any part or aspect of this data or website. Our authorized representatives and affiliated partners and/or and companies or employees are not responsible and not liable for any decisions, treatments, costs or physicians/surgeons/facilities fees to which the physician or patient/individual recommend or select. Once again, this information is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition.